Moreover, animal models of lung cancer have shown that mice treated with anti-resistin antibodies exhibited reduced rates of lung cancer development and metastasis (181), further proving that resistin, by modulating inflammatory responses in the tumor microenvironment, indirectly facilitates lung cancer bone metastasis. This evidence concerns the gene RETN and lung carcinoma.